Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced “Eosinophilic Fasciitis-Like” Case and a Review of the Literature

Immune checkpoint inhibitors are a promising new therapeutic strategy in oncology that aims to eliminate cancer cells by enhancing patients' immune response against tumor antigens. Despite their beneficial effects, immune checkpoint inhibitors are also responsible for a plethora of autoimmune m...

Descripción completa

Detalles Bibliográficos
Autores principales: Salamaliki, Christina, Solomou, Elena E., Liossis, Stamatis-Nick C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695772/
https://www.ncbi.nlm.nih.gov/pubmed/33067734
http://dx.doi.org/10.1007/s40744-020-00246-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695772/
https://www.ncbi.nlm.nih.gov/pubmed/33067734
http://dx.doi.org/10.1007/s40744-020-00246-z

Ejemplares similares